LDL-cholesterol lowering medication linked to lower mortality in high-risk patients

Mass General Brigham Heart and Vascular Institute researchers person recovered that high-risk patients who had not antecedently experienced a bosom onslaught oregon changeable had a little hazard of decease aft taking the cholesterol-lowering cause evolocumab (on apical of modular cholesterol-lowering therapy) arsenic portion of a objective trial, compared with those taking a placebo. Results were presented astatine the ESC Congress 2026 and simultaneously published successful Circulation.